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Abstract
Bioethics falls within the controversial ethical issues from the new advances and emerging technology in pre-clinical
and clinical settings which inspired medical policy and practice. The purpose of this paper is to present an overview of
ethical issues in stem cell-based therapies and to provide substantial argument for the need of a Bioethics Research
Consortium that will be tasked with convening a disciplined board of experts that will apply their principles to
biomedical research, and emerging technology to further stipulate the socioeconomic influence of such entities
and their therapeutic impact to society. Not too long ago, the successful therapeutic studies in Parkinson’s
disease and stroke were the highlights of bioethical issues. The precedent for study selection was based on
public feedback, government reception, and scientific analyses developed by these spearhead studies. From all
the negative publicity that researchers have been getting before, the whiplash from decades of fear and
misunderstanding has hindered the progress of scientific study. There is a huge figurative tug of war between
what is making profit and what is needed to improve the health of afflicted patients worldwide. Poor management of
education and funding may have actually hindered potential life changing cures and treatments from coming to
fruition. We propose the creation of a Bioethics Research Consortium that would determine how ethical matters are
handled with careful consideration to public need. The goal is to restructure drug development policy, and improve
upon the ways in which research methods and funds are handled today.
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Background
With novel discoveries and technological advances, there
will come new legal, social, and ethical issues. Prior to
the breakthroughs that helped advance the scientific
communities to publicly display the need for their re-
search, media coverage was unfortunately ill-managed
and ethical concerns emerged as a result. Negative media
coverage has led to public concerns that may have been
misconstrued, and pre-clinical/clinical progress of novel
treatment studies has been averted despite the favorable
intent behind such studies. Cell based therapies have been
studied for decades and have only recently caught the
disinterest of the public opinion in the late 1980s. Public
concern arose during the period of human fetal tissue
being harvested from elective and spontaneous abortions
that were obtained for the purpose of donor cell trans-
plantations in Parkinson’s disease (PD). One of the few
medical centers world-wide that would conduct fetal
cell transplantation was the University of South Florida
Department of Neurosurgery and Brain Repair [1, 2].
We were well aware of the ethical concerns that were
surrounding fetal tissue research, bearing particular
sensitivity to the public’s views on aborted fetal tissues,
as well as the approach handled in regards to donor
mothers [3]. There were other research academies such
as Georgetown University that would contend to the
use of fetal tissue in research and medical treatment
procedures on the grounds of ethical and scientific study.
Public opinion and media coverage hugely distorted the
scientific reports, claiming that the use of fetal tissue used
in medical treatments, as well as research, would not only
display no regenerative properties, but would even
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exacerbate the symptoms of PD patients in comparison to
the control group [4]. There were many counterclaims via
the standpoint articles and stem cell community discus-
sions from the research community, including that of the
USF department of Neurosurgery and Brain repair. USF
called for the resolution of these “negative” connotations
to clarify that some studies involving cells implanted in
patients were prepared adversely compared to other stud-
ies involving fetal cell transplant procedures, due to a lack
of extensive cell culture manipulation. Severity of patient
illness, and stem cell dosage need to be taken into careful
consideration when troubleshooting stem cell transplant-
ation protocols [5, 6]. In conclusion, it is critical to handle
the entire stem cell transplantation scenario properly, and
adhere to the ethical issues in a proper manner so that
stem cell treatment outcomes do not confuse the general
public about the clinical findings and studies.
Bioethical issues that accompany cell therapy
over the last Two decades
There were several concerns raised against the use of
fetal tissues. For instance, several fetuses were needed in
order to transplant them into a single patient. In order
to resolve this issue, an alternate non-fetal cell sources
was sought out. The alternative was to find nonfetal cell
sources that could differentiate, being able to be manufac-
tured under quality control, and guaranteed conditions in
order to have an ample and clinical grade nonfetal stem
cell supply for transplantation. This kind of approach has
many practical implications that would not only avoid
ethical concerns, but also solves the public health and
research/scientific problems that commonly arise when
using a limited source of stem cells such as fetal cells.
Accordingly, we provided crucial research studies for
the world’s first clinical trials allowed by the U.S. Food
and Drug Administration (FDA) whereby cultured hu-
man neural progenitor cells were implanted in patients
suffering from stroke [7, 8]. However, the problem was
that these cells were immortalized neural cells, leading
to public concerns of tumorigenesis [9, 10]. Therefore,
safety because the number one concern in cell therapy
controversy.
The search for a nonfetal safe and reliable cell source
brought about the research on embryonic stem cell ther-
apy. Once again, cell-base therapy was filled with con-
troversy which attracted the public attention. The main
point of controversy was the lack of knowledge and
communication to understand the difference between an
embryo and fetal tissue, arguing that an embryo is in fact
when human life begins. During this very debate, the
media was setting the stage for an even greater public
outcry of fear that stem cell research could develop and
eventually reach the stages of human cloning. Therefore,
this preconceived notion of human cloning led to the
idea that human embryonic cell-based therapies would
not only violate human rights but also human dignity.
The research community took yet another blow when
the National Institute of Health (NIH) was pigeon-holed
as a result of the ban on funding to further support em-
bryonic stem cell research. Through the Bush administra-
tion, this ban was thoroughly upheld for 8 consecutive
years [11].
The strengths and weaknesses of stem cell-based ther-
apy research was discussed in order to restart initiatives
among states for funding. One of the most active states
was California, which passed a legislation for the contin-
ual funding of embryonic stem cell research [12]. Mean-
while, nonembryonic adult stem cell research gained
public and policy maker interest and thrive relative to
embryonic stem cells [13, 14], with the FDA’s approval
of clinical trials in 2008 on our pre-clinical trial data on
human bone marrow derived cell research [15]. This
progression in stem cell research however lasted only
until March 2009, when President Barack Obama put a
hold on stem cell research funding, stating that there
has been no sign of potential use or progression of stem
cell studies that resulted in reliable data and treatment
methods since funding was allocated [16]. Ergo, The
NIH released the Guidelines for Human Stem Cell Re-
search, which was put into effect on July 7, 2009 [17].
The media has a heavy influence when it comes to
public opinion and cell-based therapies. These influences
include an exploited absence of successful communica-
tion between the public and the scientific community,
and immediate reactive resolutions by policy makers to
gain popularity. The focal point of this flaw lies not
within changing of opinions due to the media or policy
makers, it lies within the need for a proper solution for
the public dialog and policy making as technologies ad-
vance. Developing technologies are most stifled when
the public is fearful of the new scientific breakthrough,
or sets unrealistic goals that give a sense of false hope.
These reservations are not always without validity, but
the media often uses this as an opportunity to increase
its ratings in light of the controversy. This is usually the
case for stem cell based therapies, and the newly advan-
cing technologies that revolutionize healthcare.
There is an underrepresentation of benefits for stem
cell based therapies due to social, legal, and ethical issues.
Consideration for privacy, risk analysis, intellectual prop-
erty and many other categories have not been sufficient in
terms of policy development or assessment protocols that
involve stem cell therapy. This means that there is no solid
guidance on prerequisites to satisfy ethical issues for large
scale funding including NIH and the FDA.
The establishment of an Ethics Research Consortium
for Emerging Technologies will bring forth guidance and
understanding by identifying and analyzing legal, social,
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and moral issues and through an interdisciplinary
method. (See Fig. 1) This clarity will lead to a deeper re-
spect and appreciation that will guide policy makers and
public misperception. The consortium will address is-
sues such as confidentiality of tissue donors, safety con-
cerns about tumorigenesis in stem cell transplantation,
conflicts of interest, intellectual property of patented
stem cell lines, and the commercialization of stem cells.
Once these issues are properly addressed they may be
able to offer guidelines for stem cell research for the
NIH and FDA.
Public opinion is not an easy issue to address when
speaking on the issues of stem cell therapy. The first
challenge to be addressed by the consortium will be the
determination of what public opinion truly is for stem
cell based research and stem cell based therapies. Once
that is established, there are three things that must be
answered: 1) what is the best way to recognize and in-
corporate public opinion and policy making; 2) deter-
mining the overall benefit of the research in the midst of
a multitude of different opinions; and 3) whether there
can be an integration of education and ethical public
opinions that can lead to a common good.
In order to successfully accomplish this groundwork
the consortium will need to establish baseline data on
public opinion by conducting three initial focus groups
with opinion leaders (The Baseline Focus Group). This
means that the focus groups cannot be generalized, but
key issues will be identified and further explored. A sec-
ond set of three community focus groups (Educational
Focus Group), with the same individuals from the Baseline
Focus Group, will be educated by the consortium. Educa-
tion will include scientific information and policy recom-
mendations developed by the panel from the feedback of
the Baseline Focus Group. The focus group members will
then be asked to return to their communities to think
about the issues at hand. After a reasonable amount of
time has passed, a final focus group will be made (The
Educational Follow-up Focus Group). This group will
give their feedback that will be incorporated into the
final policy of the Consortium Report.
The secondary interviews will determine will assess
beliefs, opinions, and concerns about stem cell uses by
using the same questions asked in the Baseline Focus
Groups. The data collected will determine if the educa-
tion provided was impactful their original conclusions.
In order to confirm the data, each of the focus group
members which participated in all of the first three
groups will be asked to determine who in their associ-
ation will be inclined to aid in the final focus group to
baseline opinions on stem cell research and its potential
therapies. The beginning focus group members will be
tasked to arrange educational materials that will be pre-
sented to the constituents in a kit that will contain all of
the following: A brochure that contains explanations to
the scientific information, recommendations that is ex-
pertly crafted by the Panel that addressed ethical issues,
links that identified informational website (s) where the
ethical issues are addressed, and other training modules
that are determined by the Conglomerate. Than the ini-
tial group members will be needed to debate the issues
with the established board. Next the Conglomerates will
oversee a Conglomerate Opinion Focus Group with the
mindset of achieving the guideline opinions, beliefs,
concerns, and views of the board about stem cell-based
tissue engineering. In addition, data collected data will
be analyzed to determine the beliefs, opinions, and
views the board focus group members may have. This
approach was necessary in order to assess whether the
majority opinion on ethical issues represents in the se-
lected focus groups is fixed, or if it changes in correlation
to the educational materials given on scientific data, as
well as the groups’ analysis on the pros and cons of the re-
lated research.
The basis for creating an Ethic Research conglomerate
is so that we can establish a proactive public conclusion
about stem cell research. Which in turn would form the
structure for revisions to or creation of an intuitional
state, or even national regulatory procedure that grows
in parallel to the rapid progression of technological ad-
vances and discoveries. The stem cell Conglomerate
should not only be able to recognize various grounds that
would address all the critical barriers that the community
and researchers may face, but also to achieve a consensus
between the two society where any unanswered questions
Fig. 1 Consortium bioethical issues based on stem
cell-relevant therapies
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may linger. For instance, government policies are highly
persuaded by the mass media, whose misperceptions
about stem cell-based therapies are communicated to
them and the general public. The concept of the Con-
glomerate’s design is to link the gap between the general
public ideas of what is the “common good” and to provide
scientific facts and correct information not only the mass
media but also to the government. Therefore providing
the public with evidence based on ethical tools for policy
constructing. In order to keep up with various challenges
that is brought up with emerging technological advances,
the Conglomerate must tackle the situation head on with
multiple spearhead approaches. This strategy will not only
be able to steer public symposiums but also to critically
observe the social costs that alternative options may hold.
Develop training programs on the ethics of emerging tech-
nologies all the while focused on the overall goal of closing
the gap between science and the “common good” as well
informed and educated individuals approach making gov-
ernment policies through evidence based ideals.
The bases for the Consortium will be formed within
an educational/research institution which will be inte-
grated by ethicists, academic scientists, experts on policy
making, as well as leaders from both public and private
opinion. Through the use of surveys and discussion
based forums, assessing the public opinion, we can use
ethical criterions that were mentioned above (e.g., Intel-
lectual property, commercialization, the common good,
research participation, risk analysis, privacy, and con-
flicts of interests), to form the framework for suggestions
towards the Conglomerate and its regular oversights. In
order to establish this message, a position paper will be
published in the peer-reviewed journal, and send as an
open letter to the FDA, NIH, and other agencies in stem
cell research. The strategy is to tackle the current guide-
lines with available NIH and FDA agencies to comprom-
ise and have an overview that would satisfy the public
and ethical issues that surround stem cell research for
grant protocol and IND applications.
Through this proposed Conglomerate, the public opin-
ion will be able to get integrated and recognized into the
policies concerning stem cell research. The goal is to let
the public and funding agencies comprehend our results
aiming to the promotion of accountability of stem cell
research and its need for public funding.
Conclusion
In conclusion, the overall goal of the Ethics Research
Conglomerate is to merge public opinions and desires
with researching methods and goals to reach a continually
evolving process as technology and societal views changes.
Utilizing an evidence-based study and a proactive govern-
ment policy making in response to proper communication
between researchers and the mass media to the public.
The Conglomerate’s efforts will be the evidence necessary
in order to prove for the need for an ethics board within
an institution that is assigned with the application of eth-
ical questions in terms of technology by certain ruling
panels. The efforts of the Conglomerate is in stem cell
technology advances and pits proposed research tools
such as public forums, risk assessments, surveys, and
interviews can be later modified as societal views
changes and technology advances. Such as bioengin-
eering and nanomedicine [18, 19]. A small scale trial
study for the Conglomerate can begin at the commu-
nity level and eventually reach a more large-scale
study that should target a national level as the end de-
sire for a better understanding of nations opinion on
such emerging technological advances. This transition
from community level to a national scale that reflects
the benefits from a philosophical standpoint and pol-
icy reflections of involved democracy. In order to have
the Conglomerate at such a scale, it is critical to
present a solid and comprehensive guide from the
American population that will be critical to the policy
procedures of the public. Lastly, the awareness that
with rapid progression of medical breakthroughs in
stem cell research, would not only be at the mercy of
the socioeconomics and political motives, but as well
as public opinion. These are all the keys that open the
doors to an assembly of a proper Conglomerate to
promote better coordination with the public opinion
and its policies to ensure that the public communica-
tion does not inhibit the progression of stem cell re-
search for the greater good of the public.
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